当前位置:
Mitomycin C

Mitomycin C

0.00
0.00
  
商品描述
Description

Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit DNA synthesis.

 IC50 & Target

DNA synthesis

In Vitro

The HCT116 (p53-/-) cells are minimally sensitive to either Mitomycin C or TRAIL alone. However, surprisingly, combination treatment with MMC and TRAIL decreases cell viability significantly. Although Mitomycin C and TRAIL alone are moderately effective, Mitomycin C substantially enhances the effect of TRAIL on suppression of the cell proliferation. Mitomycin C and TRAIL treatment alone induces 9.5% and 35.0% apoptosis, respectively. However, combination treatment with Mitomycin C and TRAIL enhances apoptosis to 66.6%[1]. Mitomycin C is a cytotoxic chemotherapeutic agent that causes DNA damage in the form of DNA cross-links as well as a variety of DNA monoadducts and is known to induce p53[2].

In Vivo

Mice bearing xenografted HCT116 (p53-/-) colon tumors and HT-29 colon tumors are treated with Mitomycin C (i.p., 1 mg/kg) and TRAIL (i.v., 100 μg) every other day. Animals are treated with 10 consecutive cycles of the combination therapy regimen. The combination therapy suppresses tumor growth significantly and does not impact the weight of the mice, indicating that the therapeutic combination of Mitomycin C and TRAIL is well-tolerated and has anti-tumor activity in vivo[1]. Intravesical Mitomycin C instillations has an effect on body weight that is not observed in normal, NaCl instilled or Epirubicin instilled rats. After 3 consecutive weekly instillations of 1 mg/mL Mitomycin C there is almost no weight gain, whereas rats in the other 3 groups has a statistically significant weight gain compared with MMC treated rats.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00005944 UNICANCER|National Cancer Institute (NCI) Colorectal Cancer|Metastatic Cancer|Primary Peritoneal Cavity Cancer November 1999 Phase 2
NCT00551824 Federal University of São Paulo Esophageal Stricture|Caustic Esophageal Stricture|Peptic Esophageal Stricture|Post-Surgical Esophageal Stricture October 2007 Not Applicable
NCT01263834 Prince of Songkla University Glaucoma December 2010 Phase 2|Phase 3
NCT00346489 Indiana University School of Medicine|Indiana University Glaucoma September 2004 Phase 4
NCT01327521 Albert Koong|Accuray Incorporated|Stanford University Carcinoma, Hepatocellular February 2011 Phase 3
NCT03101501 Key-Whitman Eye Center Presbyopia February 14, 2017 Phase 4
NCT00599950 Asociación para Evitar la Ceguera en México Refractive Disorders January 2007 Phase 4
NCT00734994 Mark Dewhirst|Duke University Transitional Cell Carcinoma of Bladder|Superficial Bladder Cancer April 2008 Early Phase 1
NCT02311101 The University of Texas Health Science Center at San Antonio Urinary Bladder Neoplasm March 2012 Phase 1
NCT00666237 University of Miami|Abbott Medical Optics|Research to Prevent Blindness|National Eye Institute (NEI) Glaucoma April 2008 Not Applicable
NCT00025090 University College London (UCL) Cancer Institute|National Cancer Institute (NCI) Anal Cancer March 2001 Phase 3
NCT00423293 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Anal Cancer December 2006 Phase 2
NCT03348969 Jørgen Bjerggaard Jensen|Aarhus University Hospital Bladder Cancer November 1, 2017 Phase 3
NCT01580410 Wake Forest University Health Sciences|National Cancer Institute (NCI) Carcinoma of the Appendix|Primary Peritoneal Cavity Cancer May 2009 Phase 2
NCT03092518 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Gastric Adenocarcinoma|Esophagogastric Junction|Gastric Cancer June 5, 2017 Phase 2
NCT03548805 L.V. Prasad Eye Institute Open Angle Glaucoma September 1, 2018 Not Applicable
NCT00003596 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Southwest Oncology Group|North Central Cancer Treatment Group Anal Cancer October 1998 Phase 3
NCT02948543 University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cancer Australia Bladder Cancer July 2013 Phase 3
NCT00265863 Masonic Cancer Center, University of Minnesota Metastatic Cancer August 2004 Phase 2
NCT03274024 Singapore Eye Research Institute|National Medical Research Council (NMRC), Singapore Glaucoma September 28, 2016 Not Applicable
NCT00004209 Cancer Research UK|National Cancer Institute (NCI) Lung Cancer May 1998 Phase 3
NCT02901236 Athens Vision Eye Institute Glaucoma January 2014 Phase 2|Phase 3
NCT02695771 Spectrum Health Hospitals Urinary Bladder Neoplasms April 2016 Phase 3
NCT02287389 Tang-Du Hospital|Changhai Hospital|The First Affiliated Hospital of Guangzhou Medical University|Xinqiao Hospital of Chongqing|China Meitan General Hospital|Micro-Tech (Nanjing) Co., Ltd. Obstructive Airway Disease December 2014 Not Applicable
NCT02369939 University of Erlangen-Nürnberg Medical School Anal Carcinoma December 2014 Phase 3
NCT00024349 University Hospital Birmingham|National Cancer Institute (NCI) Bladder Cancer June 2001 Phase 3
NCT01808495 Far Eastern Memorial Hospital Function of Mitomycin C in Cornea August 2012
NCT00023842 European Organisation for Research and Treatment of Cancer - EORTC Bladder Cancer June 2001 Phase 2
NCT00966056 Karnataka Institute of Medical Sciences Nasal Synechiae|Adhesions of Nasal Cavity|Nasal Adhesions|Tissue Adhesions October 2007 Phase 2
NCT00005825 Raghu Nandan, M.D., Inc|National Cancer Institute (NCI) Lung Cancer September 1998 Phase 2
NCT00075699 Medical Research Council|National Cancer Institute (NCI) Malignant Mesothelioma September 2003 Phase 3
NCT00918528 Hillel Yaffe Medical Center Urethral Stricture June 2009 Phase 1|Phase 2
NCT00023868 American College of Radiology Imaging Network|National Cancer Institute (NCI) Colorectal Cancer|Metastatic Cancer November 2001 Phase 3
NCT00042887 European Organisation for Research and Treatment of Cancer - EORTC Bladder Cancer May 2002 Phase 3
NCT03658304 University of Florida Urothelial Carcinoma December 5, 2018 Phase 2
NCT00318643 Halozyme Therapeutics Bladder Cancer March 2006 Phase 1|Phase 2
NCT00004887 The Christie NHS Foundation Trust|National Cancer Institute (NCI) Lung Cancer January 1999 Phase 3
NCT00003240 National Cancer Institute (NCI) Lung Cancer October 1995 Phase 3
NCT00003710 The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific August 1998 Phase 1
NCT00003209 European Organisation for Research and Treatment of Cancer - EORTC|Medical Research Council Cervical Cancer December 1997 Phase 3
NCT01167725 Walter Reed Army Medical Center|National Cancer Institute (NCI) Colorectal Cancer August 2010 Phase 3
NCT00192049 Eli Lilly and Company Superficial Bladder Cancer December 2003 Phase 2
NCT02710734 Fox Chase Cancer Center Urothelial Carcinoma of the Bladder February 24, 2016 Phase 2
NCT00002993 Gynecologic Oncology Group|National Cancer Institute (NCI) Sarcoma August 1997 Phase 2
NCT01621217 Lund University Hospital|Merck Sharp & Dohme Corp. Locally Advanced Cancer in the Anal Region June 2012 Phase 1
NCT01648010 UroGen Pharma Ltd. Carcinoma of Urinary Bladder, Invasive November 2011 Not Applicable
NCT03664869 Turku University Hospital|Finnbladder Bladder Cancer October 26, 2018 Phase 3
NCT00289445 University Hospital Tuebingen Gastrointestinal Neoplasms|Neoplasm Metastasis September 1999 Phase 1|Phase 2
NCT00652860 Mayo Clinic|National Cancer Institute (NCI) Metastatic Cancer|Sarcoma August 2001 Phase 2
NCT00893490 Shahid Beheshti University of Medical Sciences Refractory Glaucoma Phase 1
NCT00276744 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) Pancreatic Cancer October 2005 Phase 2
NCT00201747 Ohio State University Comprehensive Cancer Center|Pharmacia and Upjohn Esophageal Cancer|Esophagus Cancer|Cancer of Stomach|Stomach Cancer September 2001 Phase 2
NCT00002507 Yale University Carcinoma of Unknown Primary|Head and Neck Cancer November 1992 Phase 3
NCT00271011 University of Michigan Rogel Cancer Center Colorectal Cancer December 2005 Phase 2
NCT03330028 M.D. Anderson Cancer Center Diseases of Oesophagus Stomach and Duodenum October 27, 2017 Phase 1
NCT03073694 University of Kansas Medical Center Cancer, Appendiceal|ColoRectal Cancer July 14, 2017 Phase 2
NCT01115517 The University of Texas Health Science Center, Houston|Hermann Eye Center Pterygium October 2010 Phase 2
NCT02316171 Viralytics Non-muscle Invasive Bladder Cancer December 2014 Phase 1
NCT01011010 UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) Liver Cancer July 22, 2009 Phase 1
NCT00999973 Shahid Beheshti University of Medical Sciences Myopia September 2009 Phase 1
NCT03540953 Fauze Maluf Filho|Instituto do Cancer do Estado de São Paulo Esophageal Stenosis|Deglutition Disorders|Head and Neck Neoplasms|Esophageal Neoplasms January 5, 2015 Not Applicable
NCT00967291 IRCCS San Raffaele Pancreatic Cancer March 2006 Phase 2
NCT02070120 Institute of Cancer Research, United Kingdom|National Institute for Health Research, United Kingdom Bladder Cancer October 2014 Phase 2
NCT00003893 University Hospital Birmingham|National Cancer Institute (NCI) Breast Cancer July 1998 Phase 3
NCT03381352 Chinese Academy of Medical Sciences Anal Cancer December 2, 2015 Phase 2
NCT00597181 Indiana University|Optonol Glaucoma November 2007 Phase 4
NCT00854256 University of Cologne|iScience Interventional Corporation Glaucoma April 2009 Not Applicable
NCT00003159 Medical Research Council|European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) Lung Cancer August 1997 Phase 3
NCT00306852 University of Miami|Pfizer|Abbott Medical Optics Glaucoma October 1999 Not Applicable
NCT00033644 Gynecologic Oncology Group|National Cancer Institute (NCI) Sarcoma March 2002 Phase 2
NCT01200992 Bioniche Life Sciences Inc. Bladder Neoplasm|Neoplasm Recurrence, Local|Transitional Cell, Carcinoma|Carcinoma in Situ|Mycobacterium November 2010 Phase 3
NCT00024271 Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) Malignant Mesothelioma May 2001 Phase 2
NCT00030459 British Thoracic Society|Medical Research Council|National Cancer Institute (NCI) Malignant Mesothelioma November 2000 Phase 2
NCT00002490 Medical Research Council|National Cancer Institute (NCI) Bladder Cancer September 1991 Phase 3
NCT02199327 Coordinación de Investigación en Salud, Mexico|Instituto Mexicano del Seguro Social|University of Guadalajara Conjunctival Intraepithelial Neoplasia|Corneal Intraepithelial Neoplasia May 2014 Phase 4
NCT00068744 European Organisation for Research and Treatment of Cancer - EORTC Anal Cancer July 2003 Phase 2|Phase 3
NCT03604653 Holy Name Medical Center, Inc. Stomach Cancer|Colorectal Cancer|Appendiceal Cancer|Ovarian Cancer|Uterine Cancer|Cervical Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma May 15, 2018
NCT02092298 M.D. Anderson Cancer Center Gastrointestinal Cancer May 2014 Phase 2
NCT00003003 Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI) Leukemia September 1996 Phase 1
NCT03126877 Whitten Laser Eye Presbyopia April 10, 2017 Phase 4
NCT01688024 Li, Zhiping, M.D.|Johns Hopkins University Primary Sclerosing Cholangitis September 2012 Phase 2
NCT02040142 Albert Einstein College of Medicine, Inc. Peritoneal Carcinomatosis|Colorectal Cancer|Appendiceal Cancer|Peritoneal Mesothelioma|Pseudomyxoma Peritonei|Gastric Cancer November 2011 Phase 2
NCT03242317 Fichte, Endl & Elmer Eyecare Presbyopia June 16, 2017 Phase 4
NCT02641132 Meir Medical Center Pterygium September 2015 Phase 4
NCT01094964 Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI) Bladder Cancer October 2009 Phase 3
NCT00006112 Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI) Carcinoma of the Appendix|Colorectal Cancer|Primary Peritoneal Cavity Cancer January 1996 Phase 2
NCT03506542 Medical University of Lublin|Aeon Astron Europe B.V. Glaucoma|Cataract|Wound Heal June 2, 2014 Phase 2
NCT00949182 Rutgers, The State University of New Jersey Liver Cancer July 2009 Phase 2
NCT00974818 Memorial Sloan Kettering Cancer Center|New York Presbyterian Hospital|Weill Medical College of Cornell University Bladder Cancer September 2009 Phase 3
NCT00981656 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Bladder Cancer November 2009 Phase 2
NCT01042041 Abramson Cancer Center of the University of Pennsylvania Hepatocellular Carcinoma|Liver Cancer|Localized Unresectable Liver Cancer September 2009 Phase 1
NCT00003018 Southwest Oncology Group|National Cancer Institute (NCI) Pancreatic Cancer September 1997 Phase 2
NCT00005870 Astex Pharmaceuticals|National Cancer Institute (NCI) Pancreatic Cancer March 1999 Phase 3
NCT01196455 Croatian Cooperative Group for Clinical Research in Oncology|Roche Pharma AG Breast Cancer|Metastasis March 2006 Phase 2
NCT02106572 Abnoba Gmbh Superficial Bladder Cancer February 2015 Phase 3
NCT00564213 Instituto de Olhos de Goiania High Myopia March 2005 Phase 4
Solvent & Solubility
In Vitro: 

DMSO : 30 mg/mL (89.73 mM; Need ultrasonic and warming)

Preparing
Stock Solutions
ConcentrationSolventMass 1 mg 5 mg 10 mg
1 mM 2.9911 mL 14.9553 mL 29.9106 mL
5 mM 0.5982 mL 2.9911 mL 5.9821 mL
10 mM 0.2991 mL 1.4955 mL 2.9911 mL
*Please refer to the solubility information to select the appropriate solvent.

相关产品:
品牌
货号
名称
规格
MCE
HY-100406-50MG
(S)-MCPG
 
MCE
HY-100421
CPI-455
5MG
MCE
HY-10071-1ml
Y-27632
1ml
MCE
HY-10071-50mg
Y-27632
50mg
MCE
HY-10108
LY294002
10 mM * 1 mL
MCE
HY-101091-5mg
Importazole
5mg
MCE
HY-101391-100mg
Picrotoxin
100mg
MCE
HY-101494-1MG
LY3214996
 
MCE
HY-10182 -1ml
CHIR-99021
1ml
MCE
HY-10219-10MG
Rapamycin
 
MCE
HY-10219-25MG
Rapamycin
 
MCE
HY-10254-1ml
PD0325901
1ml
MCE
HY-10358
MK 2206 dihydrochloride
10 mM * 1 mL
MCE
HY-10583-1ml
Y-27632 (dihydrochloride)
1ml
MCE
HY-10627A-50mg
GW3965 hydrochloride
 
MCE
HY-10627A-5MG
GW3965 hydrochloride
 
MCE
HY-108709 -1mg
CC-671
1mg
MCE
HY-10997-10MG
PCI-32765
 
MCE
HY-12028
PD98059
10 mM * 1 mL
MCE
HY-12028-5MG
PD98059
 
MCE
HY-12275
FR 180204
10 mM * 1 mL
MCE
HY-12466-1mg
Z-DEVD-FMK
1mg
MCE
HY-12526
Tetrodotoxin
1MG
MCE
HY-13315-50MG
Montelukast sodium
50MG
MCE
HY-13316
Mitomycin C
5MG
MCE
HY-13688A-10MG
PJ34
 
MCE
HY-14166-100MG
MK-886
 
MCE
HY-15310-500mg
Ivermectin
500mg
MCE
HY-15893-50mg
DMOG
50mg
MCE
HY-16563-1mg
Narciclasine
1mg
MCE
HY-17026-100mg
Gemcitabine
100mg
MCE
HY-17356-10g
Fenofibrate
 
MCE
HY-17382
Metoclopramide
100MG
MCE
HY-17538-10MG
ZLN005
10MG
MCE
HY-17561-5G
G-418 disulfate
5G
MCE
HY-17567-100mg
Heparin
100mg
MCE
HY-17567A-100mg
Heparin sodium salt
100mg
MCE
HY-17589-100MG
Chloroquine diphosphate
 
MCE
HY-18012
AVL-292
10MG
MCE
HY-19312-500MG
3-Methyladenine
 
MCE
HY-19312-50mg
3-Methyladenine
50mg
MCE
HY-19538-1mg
FRAX1036
1mg
MCE
HY-50846-2MG
SCH772984
 
MCE
HY-50907-1ml
ABT-737
1ml
MCE
HY-66009-1ml
Epalrestat
1ml
MCE
HY-B0089
Acarbose
200MG
MCE
HY-B0141-1G
Estradiol
1g
MCE
HY-B0795-5MG
MHY1485
 
MCE
HY-B0919-1ml
Azaserine
1ml
MCE
HY-B1041-1ml
Aminoguanidine hydrochloride
1ml
MCE
HY-B1743A
Puromycin dihydrochloride
10 mM * 1 mL
MCE
HY-B1756-5g
Rotenone
5g
MCE
HY-N0219
(+)-Bicuculline
100MG
MCE
HY-N0390-100mg
L-Glutamine
100mg
MCE
HY-N0583 -1G
Hydrocortisone
1g
MCE
HY-P0035-10mg
Insulin(human)
10mg
MCE
HY-P7011-10ug
Recombinant Human Epiregulin
10ug
MCE
HY-P7154-10ug
Recombinant Mouse DKK-1 (CHO-expressed)
10ug